Sugi Predict

Sugi Predict / Compounds / SCHEMBL1012154

SCHEMBL1012154

SCHEMBL1012154

COCC(C)(C)C(=O)OC

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 3/20 0.41
▸ TSHR P16473 3/20 0.33
▸ PRSS1 P07477 1/20 0.32
▸ CTSG P08311 1/20 0.32
▸ CTRB1 P17538 1/20 0.32
▸ CMA1 P23946 1/20 0.32
▸ KCNN4 O15554 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ HTR1A P08908 2/20 0.31
▸ DRD2 P14416 2/20 0.31
▸ DRD4 P21917 2/20 0.31
▸ HSD17B10 Q99714 1/20 0.31
▸ MGAM O43451 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ SI P14410 1/20 0.31
▸ MGAM2 Q2M2H8 1/20 0.31
▸ KCNH2 Q12809 1/20 0.30
▸ TET2 Q6N021 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17574066 0.86 DGAT1 (0.42) DGAT1TSHRPRSS1CTSGCTRB1
SCHEMBL25476756 0.84 PRSS1 (0.40) DGAT1PRSS1CTSGCTRB1CMA1
SCHEMBL2183590 0.81 DGAT1 (0.35) DGAT1TSHRPRSS1CTSGCTRB1
SCHEMBL2031592 0.81 DGAT1 (0.42) DGAT1TSHRKCNN4ALDH1A1HSD17B10
SCHEMBL14536444 0.80 DGAT1 (0.38) DGAT1TSHRPRSS1CTSGCTRB1
SCHEMBL18553040 0.80 DGAT1 (0.38) DGAT1TSHRPRSS1CTSGCTRB1
SCHEMBL1691335 0.80 DGAT1 (0.38) DGAT1TSHRPRSS1CTSGCTRB1
SCHEMBL11930048 0.80 DGAT1 (0.43) DGAT1TSHRPRSS1CTSGCTRB1
SCHEMBL24242159 0.80 DGAT1 (0.48) DGAT1
SCHEMBL19457901 0.80 DGAT1 (0.38) DGAT1TSHRPRSS1CTSGCTRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4741018-A2 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2026-05-13 — — EP disclosed
US-12583836-B2 Sulphonamide compounds Anaxis Pharma Pty Ltd (AU) 2026-03-24 — — US disclosed
EP-4168401-B1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2026-01-07 — — EP disclosed
US-20250074891-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2025-03-06 — — US disclosed
EP-4452966-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2024-10-30 — — EP disclosed
US-20230227429-A1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-07-20 — — US disclosed
US-20230227429-A1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-07-20 — — US disclosed
WO-2023115149-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-06-29 — — WO disclosed
EP-4168401-A1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-04-26 — — EP disclosed
CN-115956070-A Sulfonamide compounds 阿纳克西斯制药股份有限公司 2023-04-11 — — CN disclosed
US-7169760-B2 Peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION (US) 2007-01-30 — — US disclosed
US-20060252837-A1 Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-11-09 — — US disclosed
US-20050245565-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-03 — — US disclosed
EP-1577301-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-09-21 — — EP disclosed
US-20050119486-A1 Diamine derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2005-06-02 — — US disclosed
WO-2005021584-A2 NOVEL PEPTIDOMIMETIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS SCHERING CORPORATION (US) 2005-03-10 — — WO disclosed
US-20050020645-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-01-27 — — US disclosed
EP-1415992-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 — — EP disclosed
EP-1405852-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-07 — — EP disclosed
US-4775692-A ANTILIPEMIC, ANTICOAGULANT, HYPOTENSIVE, ANTISECRETORY AND ANTIULCER AGENT TORAY INDUSTRIES, INC. (JP) 1988-10-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252837-A1 Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X F2, C1S, C9 DGAT1 571/4885TSHR 299/4885PRSS1 166/4885
US-20050020645-A1 Diamine derivatives C9, C1S, C1R DGAT1 567/4885TSHR 516/4885PRSS1 412/4885
US-20250074891-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS MLKL, RIPK3, CASP9 DGAT1 3930/4885TSHR 4279/4885PRSS1 275/4885
US-20050245565-A1 Diamine derivatives C9, C1S, C1R DGAT1 567/4885TSHR 516/4885PRSS1 412/4885
US-12583836-B2 Sulphonamide compounds MLKL, RIPK3, CASP1 DGAT1 3750/4885TSHR 1614/4885PRSS1 1879/4885
US-20230227429-A1 SULPHONAMIDE COMPOUNDS MLKL, RIPK3, CASP1 DGAT1 3685/4885TSHR 4177/4885PRSS1 419/4885
US-20050119486-A1 Diamine derivatives C9, C1S, C1R DGAT1 567/4885TSHR 516/4885PRSS1 412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.